FDA's Acting Commissioner Seeks Trust Amid Rare Disease Sector Challenges
Acting U.S. FDA Commissioner Kyle Diamantas met with rare disease groups to rebuild relations and support for treatment developments. The groups expressed dissatisfaction with the prior leadership under Marty Makary. The meeting emphasized trust-building as Diamantas seeks a permanent role and aims for a collaborative approach with stakeholders.
In an effort to mend ties with the rare disease sector, Acting U.S. FDA Commissioner Kyle Diamantas met with representatives of rare disease organizations. The meeting, confirmed by a government official, addressed concerns and sought to build support for treatments catering to small patient populations.
Following the resignation of Commissioner Marty Makary, who clashed with the White House on various issues, Diamantas aims to bring stability and rebuild the FDA's rapport with stakeholders. Jeff Allen, CEO of Friends of Cancer Research, noted the meeting offered a 'breath of fresh air' as Diamantas listened to concerns and reinforced the agency's dedication to advancing rare disease therapies.
Attendees urged Diamantas to provide greater regulatory clarity and predictability. While no commitments were made, discussions underlined the need for innovative approaches to clinical trials and enhanced public engagement, as emphasized by a spokesperson for the Foundation for Angelman Syndrome Therapeutics.
(With inputs from agencies.)
Google News